

CIRM's Evolution and Vision for the Future

Jonathan Thomas, PhD, JD CIRM President & CEO Citizens Financial Accountability Oversight Committee (CFAOC) December 2024 CIRMA INSTITUTE FOR REGENERATIVE MEDICINE







Our Mission

Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world.





Since 2004, CIRM has funded \$3.8 billion* in regenerative medicine research, infrastructure, and education programs, making California a hub for cell and gene therapy innovation.



*As of June 30, 2024





Our Impact











85+ Diseases and conditions 9 Alpha Clinics across the state 4,300+

Interns, trainees, and fellows 50+ New businesses **56K+** full-time equivalent jobs in CA*

Prop 14-Era: Our 5-Year Strategic Plan



RM

Advance World Class Science

- Develop shared resources
- Build knowledge networks



Deliver Real World Solutions

- Advance therapies to marketing approval
- Create a manufacturing partnership network
- Expand Alpha Clinics Network
- Create Community Care Centers of Excellence

Provide Opportunity for All

- Build a diverse and highly skilled workforce
- Deliver a roadmap for access and affordability




Diversity, Equity, & Inclusion (DEI)

CIRM requires diverse representation in the projects it funds and promotes DEI values across our programs, including:

- In patient outreach and clinical trial recruitment
- In education and workforce development
- Providing access to diverse cell lines for research (iPSC Repository)
- Advancing our community outreach efforts across the state









Overview of Funding Programs & CIRM-Funded Research



Pillar Programs and Investments






*As of July 2024

Research and Development Portfolio*

- Wide variety of diseases and disorders
- Cell and gene therapies, biologics, small molecules




* FY 2023/2024



Clinical Trial Portfolio

- 111 Clinical Trials funded*
- Wide variety of diseases and disorders
- Different approaches



CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

\$1.5 Billion for Neuro Research

- **ReMIND:** <u>Re</u>search Using <u>Multidisciplinary,</u> <u>Innovative Approaches in Neuro Diseases</u>
- Allocating at least \$1.5 billion for research and development of treatments for diseases affecting the brain and central nervous system
- **\$110 million** approved to tackle complex neuropsychiatric diseases including substance use disorders in 2024-2028
- **\$67.5 million** approved in Aug 2024 to support 5 projects in pilot ReMIND Program





Building a Diverse Regenerative Medicine Workforce in California



To date, CIRM's education and training programs have supported 4,317+ interns and fellows.



CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE

Training Programs: SPARK and COMPASS

SPARK



- 11 programs across state
- High School Students
- Summer Laboratory Internship
- End of Summer Conference

COMPASS



- 16 Programs across state
- Undergraduates Sophomore/Junior
- 2-3 years support, courses + internship(s)
- Innovative Recruitment and Selection

Training Programs: Bridges and Scholars

Bridges

RM




- 15 Programs at CSUs/Comm Colleges
- Late undergrad, Masters, or special certificate
- Specialized courses, activities and outreach
- Up to 12 months internships at host sites

CIRM Scholars




- 18 programs across state, 3rd RFA
- Predoc, postdoc, clinical Fellows
- Special Courses/Outreach
- 2-3 Year Fellowships


CIRM education programs aim to **broaden participation** of individuals representing the diversity of California including **those who may not have had opportunities** and are hindered by socioeconomic constraints.





Gender Identity and First-Generation Students







Commercialization of Cell and Gene Therapies

WORK

Alpha Clinics Network: Supporting World-Class Clinical Infrastructure

 Nine leading medical centers

RM

- 250+ trials supported
- CIRM-funded and industry sponsors
- Over 2,000 patients treated
- Over \$100 million in industry contracts



Stanford MEDICINE Cityof Hope。

Alpha Clinic

UCCE

 UCDAVIS HEALTH
 Alpha Stem Cell Clinic

CIRM

ALPHA

CLINICS



Alpha Clinic

University of California San Francisco

UC Alpha Clinic







Building a California Cell and Gene Therapy Manufacturing Network

Composed of 9 CIRM-funded academic Good Manufacturing Practice (GMP) facilities in California to help overcome manufacturing bottlenecks

Goals of the network:

- Accelerate and de-risk path to commercialization
- Advance standards and quality by design
- Build manufacturing leadership and workforce

Network Members







University of California, Irvine





UCSF







Patient Support Program: Addressing Access Barriers to Trials

- \$15.6 million patient assistance fund
- Promotes equal access to CIRM-funded clinical trial
- Addresses financial and logistical challenges faced by patients and their families





Community Care Centers of Excellence: Expand Access for Underrepresented Communities


- Enable broad awareness and access to regenerative medicine treatments for patients
- Expanding access to clinical trials, treatments, and CIRM education and training programs
- Expected to launch in 2025





Forging Partnerships to Commercialize Cell and Gene Therapies





- Sickle Cell: Affects around 100,000 in the U.S. & millions worldwide
- Four CIRM-funded trials for sickle cell:
 - Matthew Porteus, Stanford University
 - Donald Kohn, UCLA
 - Mark Walters, UCSF Benioff Children's Oakland
 - David Williams, Boston Children's Hospital
- Part of a unique partnership with the National Heart, Lung and Blood Institutes (NHLBI) under the NIH's "Cure Sickle Cell" initiative

Looking Into the Future

Strategic Allocation Framework (SAF): A structured, data-driven effort designed **to prioritize resources and maximize the impact** of CIRM's \$3.86 billion left in funding

New Impact Goals

1. **Catalyze** the identification and validation of at least 4 novel targets and biomarkers, ensuring integration into preclinical or clinical research for diseases in California

2. Accelerate development and utilization of 5-8 technologies that demonstrate improvements in safety, efficacy, or quality of cell and gene therapies

- 3. Advance at least 4-7 rare disease projects to BLA
- 4. Propel 15-20 therapies targeting diseases affecting Californians to late-stage trials
- 5. Ensure that every BLA-ready program has a strategy for access and affordability

6. **Bolster** CIRM's workforce development programs to address gaps and meet evolving demands in regenerative medicine



Thank You!

Please visit us at: www.cirm.ca.gov